Weight Loss

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are down during Tuesday’s premarket session following the Monday announcement of topline results from its EMANATE trial. EMANATE was a Phase 3 trial designed to evaluate the efficacy and safety of setmelanotide in patients with rare,...

Structure Therapeutics Inc. (NASDAQ:GPCR) shares are up during Monday’s premarket session following the release of positive topline data from the Phase 2 ACCESS II trial. The stock’s rise comes as the company reported significant weight loss results from its investigational oral drug,...

Eli Lilly and Co (NYSE:LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12. The company said internal testing detected a previously unidentified impurity formed when the two substances interact. The...

AbbVie Inc. (NYSE:ABBV) shares are trading lower on Monday. The U.S. drug maker shared topline results from a Phase 1 study of ABBV-295, a long-acting amylin analog aimed at treating obesity. In March 2025, AbbVie and Gubra A/S announced a license agreement to develop GUB014295 (ABBV-295). The...

Omada Health Inc. (NASDAQ:OMDA) shares are up in Friday’s premarket session following the announcement of its new GLP-1 Flex Care program, which aims to help employers provide access to GLP-1 medications for obesity. The company on Thursday reported fourth-quarter results that beat...

China's National Medical Products Administration has approved Pfizer Inc.’s (NYSE:PFE) ecnoglutide injection for chronic weight management in adults with overweight or obesity, marking the first approval of a cAMP-biased GLP-1 receptor agonist designed to deliver sustained weight reduction...

Roche Group AG’s (OTC:RHHBY) obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results showing up to 10.7% weight loss—below expectations and lagging leading treatments from Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Co. (NYSE:LLY). Genentech on...

Alaunos Therapeutics Inc. (NASDAQ:TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003. Data Results The latest findings from Alaunos indicate that ALN1003 has shown promising results in diet-induced obesity mouse...

Eli Lilly and Co. (NYSE:LLY) shares are down on Thursday. The company announced promising results for its oral GLP-1 medication, orforglipron. On Thursday, the Zepbound maker shared detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating orforglipron, an oral GLP-1,...

Novo Nordisk A/S (NYSE:NVO) shares are down during Wednesday’s premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027, adding pressure as broader markets edged lower. Novo Nordisk Announces...

The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (NYSE:NVO) on Tuesday shared topline results from a Chinese phase 2 trial of UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon (triple G). In March 2025, the companies inked an exclusive license...

Viking Therapeutics Inc. (NASDAQ:VKTX) shares are up on Monday, in reaction to data from Novo Nordisk A/S’ (NYSE:NVO) REDEFINE 4 Phase 3 trial of CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to tirzepatide 15 mg. Novo Nordisk’s stock hit a...

Shares of Novo Nordisk A/S (NYSE:NVO) are trading lower on Monday. One of the drugmaker’s obesity treatments failed to match Eli Lilly's tirzepatide in a Phase 3 trial. This sparked the sell-off, and Novo has broken an important support level. This means it could keep moving lower, which is...

Novo Nordisk A/S (NYSE:NVO) stock is plunging on Monday on disappointing headline data from its REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial program. After the update, Novo Nordisk stock hit its 52-week low. Over the year, the stock has fallen around 48%,...

Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for plaque psoriasis and obesity. The study demonstrated the...